Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York. Show more

Location: 535 W 24th Street, New York, NY, 10011, United States | Website: https://www.neurogene.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

311.7M

52 Wk Range

$6.88 - $37.27

Previous Close

$20.12

Open

$20.06

Volume

450,545

Day Range

$19.88 - $23.00

Enterprise Value

57.52M

Cash

265.4M

Avg Qtr Burn

-19.31M

Insider Ownership

8.54%

Institutional Own.

99.52%

Qtr Updated

09/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NGN-401 Details Rett syndrome	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NGN-101 Details Rare genetic disease, Batten Disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.